Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) announced today that it will report first quarter 2008
financial results on Wednesday, April 30, 2008, after the U.S. financial
markets close.
Anadys will hold a conference call and webcast to discuss its first
quarter 2008 financial results and highlights and to provide an update on its
development programs on Wednesday, April 30, 2008 at 5:00 p.m. Eastern
Daylight Time. A live webcast of the call will be available online at
http://www.anadyspharma.com. A telephone replay will also be available
approximately one hour after completion of the call. To access the telephone
replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode
65984063. The webcast and telephone replay will be available through May 14,
2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to
improving patient care by developing novel medicines in the areas of hepatitis
C and oncology. The Company is developing ANA598, a small-molecule,
non-nucleoside inhibitor of the NS5b polymerase for the treatment of chronic
hepatitis C, and ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include, but
are not limited to, references to Anadys' strategy, development programs, and
ability to develop novel medicines in the areas of hepatitis C and oncology.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause Anadys' actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. For example, the results of preclinical
studies may not be predictive of future results, and Anadys cannot provide any
assurances that ANA598 and ANA773 will not have unforeseen safety issues, will
have favorable results in future clinical trials or will receive regulatory
approval. Risk factors that may cause actual results to differ are discussed
in Anadys' SEC filings, including Anadys' Form 10-K for the year ended
December 31, 2007. All forward-looking statements are qualified in their
entirety by this cautionary statement. Anadys is providing this information
as of this date and does not undertake any obligation to update any forward-
looking statements contained in this document as a result of new information,
future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.

investors, James T. Glover, SVP, Operations & CFO of Anadys Pharmaceuticals,
Inc., +1-858-530-3763, jglover@anadyspharma.com; or media, Ian Stone,
ian.stone@russopartnersllc.com, or David Schull,
david.schull@russopartnersllc.com, both of Russo Partners, LLC,
+1-619-814-3510, for Anadys Pharmaceuticals, Inc.